Sale!

Imatinib Resistance Mutation Analysis IRMA Test

Name: Imatinib Resistance Mutation Analysis IRMA Test
SKU: TEST-5129
Price: 1830 AED
Availability: InStock

Original price was: 2,030 د.إ.Current price is: 1,830 د.إ.

-10%

The Imatinib Resistance Mutation Analysis (IRMA) Test is a specialized diagnostic procedure designed to identify specific genetic mutations associated with resistance to Imatinib, a medication commonly used in the treatment of certain types of cancer, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Imatinib targets and inhibits specific tyrosine kinase enzymes, which are involved in the proliferation of cancer cells. However, mutations in the genes encoding these enzymes can lead to resistance against the drug, rendering it less effective or ineffective.

The IRMA Test is crucial for patients undergoing treatment with Imatinib or those for whom the treatment is being considered. By detecting mutations, the test helps in guiding clinicians to make informed decisions regarding the use of alternative therapies or adjustments in the treatment regimen, thereby optimizing patient outcomes.

Performed at DNA Labs UAE, a state-of-the-art facility known for its advanced genetic testing services, the IRMA Test is offered at a cost of 1830 AED. The lab employs cutting-edge technology and methodologies to ensure accurate and reliable results, providing essential insights into the genetic profile of the cancer and its potential resistance to Imatinib. This personalized approach to cancer treatment underscores the importance of genetic testing in the era of precision medicine, where treatments can be tailored to the individual characteristics of each patient’s disease.

Description

IMATINIB RESISTANCE MUTATION ANALYSIS IRMA Test

At DNA Labs UAE, we offer the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test, a molecular diagnostic tool used to detect specific mutations in the BCR-ABL gene. This test is particularly important for patients with chronic myeloid leukemia (CML) who have developed resistance to the drug imatinib.

Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is responsible for the uncontrolled growth of CML cells. However, over time, some CML patients may develop resistance to imatinib due to the emergence of specific mutations in the BCR-ABL gene.

The IRMA test utilizes molecular techniques, such as polymerase chain reaction (PCR) and DNA sequencing, to identify the presence of these specific mutations. To perform the test, a blood or bone marrow sample is obtained from the patient and the DNA is isolated. The DNA is then amplified using PCR and sequenced to identify any mutations in the BCR-ABL gene.

The cost of the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test at DNA Labs UAE is AED 1830.0. The sample condition required is 4 mL (2 mL min.) of whole blood in 1 Lavender Top (EDTA) tube. It is important to ship the sample refrigerated and not freeze it. Along with the sample, please submit the latest BCR-ABL Quantitative report.

The report for the IRMA test will be delivered on Saturday, with the sample required to be submitted by Monday at 11 am. The test is conducted in our Molecular Diagnostics department, under the supervision of an Oncologist.

The results of the IRMA test can help guide treatment decisions for CML patients who have developed resistance to imatinib. If specific resistance mutations are detected, alternative treatment options, such as second-generation or third-generation tyrosine kinase inhibitors, may be considered. On the other hand, if no resistance mutations are found, it suggests that the patient’s resistance to imatinib may be due to other factors, and alternative treatment strategies may be explored.

Overall, the IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test offered at DNA Labs UAE is a valuable tool in personalized medicine. It allows for the identification of specific mutations that confer resistance to imatinib, guiding treatment decisions and improving outcomes for CML patients.

Test Name	IMATINIB RESISTANCE MUTATION ANALYSIS IRMA Test
Components
Price	1830.0 AED
Sample Condition	4 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Submit latest BCR-ABL Quantitative report along with sample.
Report Delivery	Sample Mon by 11 am; Report Sat
Method	PCR, Sequencing
Test type	Pharmacogenomics
Doctor	Oncologist
Test Department:	MOLECULAR DIAGNOSTICS
Pre Test Information	Submit latest BCR-ABL Quantitative report along with sample.
Test Details	The IMATINIB RESISTANCE MUTATION ANALYSIS (IRMA) test is a molecular diagnostic tool used to detect specific mutations in the BCR-ABL gene, which is associated with resistance to the drug imatinib in the treatment of chronic myeloid leukemia (CML). Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is responsible for the uncontrolled growth of CML cells. However, over time, some CML patients may develop resistance to imatinib due to the emergence of specific mutations in the BCR-ABL gene. These mutations alter the structure and activity of the BCR-ABL protein, making it less susceptible to inhibition by imatinib. The IRMA test utilizes molecular techniques, such as polymerase chain reaction (PCR) and DNA sequencing, to identify the presence of specific mutations in the BCR-ABL gene. The test typically involves obtaining a blood or bone marrow sample from the patient and isolating the DNA. The DNA is then amplified using PCR and sequenced to identify any mutations in the BCR-ABL gene. The results of the IRMA test can help guide treatment decisions for CML patients who have developed imatinib resistance. If specific resistance mutations are detected, alternative treatment options, such as second-generation or third-generation tyrosine kinase inhibitors, may be considered. On the other hand, if no resistance mutations are found, it suggests that the patient’s resistance to imatinib may be due to other factors, and alternative treatment strategies may be explored. Overall, the IRMA test is a valuable tool in personalized medicine, allowing for the identification of specific mutations that confer resistance to imatinib and guiding treatment decisions for CML patients.